DEVELOPMENT OF NOVEL PDE4B INHIBITORS TO TREAT ALCOHOL USE DISORDER (SBIR PHASE II)

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

• The purpose of this contract is to identify several cellular factors that have a major impact on production of a full-length HIV-1 envelope trimer without altering its native antigenic properties.
• Novel Strategies to Improve Production of a Full Length Native HIV Env Spike
• DEVELOPMENT OF NOVEL PDE B INHIBITORS TO TREAT ALCOHOL USE DISORDER
• FY 2013 Contract HHSN271201300012C, SBIR-1, Topic 003, Automated Instrument for C
• Topical Application of Hsp90 alpha Bio-modulator to Promote Healing of Soft Tissue Injuries

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

• Developing natural compound emodin as a therapy for alcoholic cardiomyopathy
• SBIR PHASE I - WEARABLE BIOSENSOR THAT QUANTIFIES BLOOD ALCOHOL CONCENTRATION IN REAL TIME
• THIS SBIR PHASE I CONTRACT IS FOR A WEARABLE ALCOHOL BIOSENSOR THAT QUANTIFIES BAC IN REAL TIME.
• Detection and Staging of Liver Fibrosis by Precise MRI (pMRI)
• Web-Based Alcohol Misuse Prevention Intervention for the Elderly

Research funding history

7 SBIR/STTR records share this UEI (2011–2019). Reported award amounts total $2,928,465. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Defense

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards